Crizotinib

(Xalkori®)

Xalkori®

Drug updated on 11/15/2023

Dosage FormCapsule (oral; 200 mg, 250 mg)
Drug ClassKinase inhibitors
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • For the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK) or ROS1-positive as detected by an FDA-approved test.
  • For the treatment of pediatric patients 1 year of age and older and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive.

Product Monograph / Prescribing Information

Document TitleYearSource
Xalkori (crizotinib) Prescribing Information.2023Pfizer Inc., New York, NY

Systematic Reviews / Meta-Analyses

Document TitleYearSource
A systematic review of the cost-effectiveness analyses of anaplastic lymphoma kinase (ALK) inhibitors in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).2023PharmacoEconomics
Comparative efficacy of alk inhibitors for treatment-naïve alk-positive advanced non-small cell lung cancer with central nervous system metastasis: a network meta-analysis.2023International Journal of Molecular
Alectinib for treating patients with metastatic ALK-positive NSCLC: systematic review and network metanalysis.2023Lung Cancer Management
Adverse Side Effects of Crizotinib in the Treatment of Anaplastic Lymphoma Kinase-Mutated Non-small Cell Lung Cancer: A Systematic Review.2023Cureus
Comparative safety of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced anaplastic lymphoma kinase-mutated non-small cell lung cancer: Systematic review and network meta-analysis.2023Lung Cancer
Safety and efficacy of alectinib versus crizotinib in alk-positive non-small cell lung cancer: An update meta-analysis.2023Pakistan Journal of Pharmaceutical Sciences
Identification of cardiotoxicity related to non-small cell lung cancer (NSCLC) treatments: A systematic review.2023Frontiers in Pharmacology
A Bayesian network meta-analysis of ALK inhibitor treatments in patients with ALK-positive non-small cell lung cancer.2023Cancer Medicine
Efficacy and safety of anaplastic lymphoma kinase inhibitors for non-small cell lung cancer: A systematic review and network meta-analysis.2023Thoracic Cancer
Risks of cardiovascular toxicities associated with ALK tyrosine kinase inhibitors in patients with non-small-cell lung cancer: a meta-analysis of randomized control trials.2023Expert Opinion on Drug Safety
Efficacy and safety of first-line treatments for patients with advanced anaplastic lymphoma kinase mutated, non-small cell cancer: A systematic review and network meta-analysis.2023Cancer
Targeted therapy for advanced anaplastic lymphoma kinase (ALK)-rearranged non‐small cell lung cancer.2022The Cochrane Database of Systematic Reviews
Toxicity profile of anaplastic lymphoma kinase tyrosine kinase inhibitors for patients with non-small cell lung cancer: a systematic review and meta-analysis.2022Investigational New Drugs
A systematic review of companion diagnostic tests by immunohistochemistry for the screening of alectinib-treated patients in alk-positive non-small cell lung cancer.2022Diagnostics
Beyond crizotinib: a systematic review and meta-analysis of the next-generation alk inhibitors as first-line treatment for alk-translocated lung cancer.2022Frontiers in Oncology
ALK inhibitors in ALK-rearranged non-small cell lung cancer with and without brain metastases: systematic review and network meta-analysis.2022BMJ Open
Comparison of Efficacy and Safety of Brigatinib in First-Line Treatments for Patients with Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Systematic Review and Indirect Treatment Comparison.2022Journal of Clinical Medicine
Crizotinib versus Alectinib for the Treatment of ALK-Positive Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.2022Chemotherapy
Comparison of clinical efficacy of alectinib versus crizotinib in ALK-positive non-small cell lung cancer: a meta-analysis.2021Frontiers in Oncology
Comparative efficacy and safety of lorlatinib and alectinib for ALK-rearrangement positive advanced non-small cell lung cancer in Asian and non-Asian patients: a systematic review and network meta-analysis.2021Cancers
First-line anaplastic lymphoma kinase (ALK) inhibitors for ALK-positive lung cancer in Asian populations: systematic review and network meta-analysis.2021Journal of Clinical Medicine
Systematic review and network meta-analysis of anaplastic lymphoma kinase (ALK) inhibitors for treatment-naïve ALK-positive lung cancer.2021Cancers
Efficacy and Safety of First-Line Treatment Strategies for Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Bayesian Network Meta-Analysis.2021Frontiers in Oncology
ALK inhibitor-induced bradycardia: A systematic-review and meta-analysis.2021Lung Cancer
Crizotinib Versus Conventional Chemotherapy in First-Line Treatment for ALK-Positive Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.2021Oncology and Therapy
Efficacy and safety of crizotinib in the treatment of advanced non-small-cell lung cancer with ROS1 rearrangement or MET alteration: a systematic review and meta-analysis.2020Targeted Oncology
Effect of alectinib versus crizotinib on progression-free survival, central nervous system efficacy and adverse events in ALK-positive non-small cell lung cancer: a systematic review and meta-analysis.2020Annals of Palliative Medicine
ALK inhibitors for non-small cell lung cancer: a systematic review and network meta-analysis.2020PLoS One
Matching-adjusted indirect comparison: entrectinib versus crizotinib in ROS1 fusion-positive non-small cell lung cancer.2020Journal of Comparative Effectiveness Research
Efficacy and safety of ceritinib in anaplastic lymphoma kinase-rearranged non-small cell lung cancer: A systematic review and meta-analysis.2020Journal of Clinical Pharmacy and Therapeutics
Final clinical guidance report: Xalkori for ROS1-positive advanced non-small cell lung cancer.2019CADTH
Crizotinib versus chemotherapy on ALK-positive NSCLC: a systematic review of efficacy and safety.2019Current Cancer Drug Targets
Meta-analysis comparing incidence of grade 3–4 neutropenia with ALK inhibitors and chemotherapy in patients with non-small-cell lung cancer.2019Future Medicine
Safety issues with the ALK inhibitors in the treatment of NSCLC: a systematic review.2019Critical Reviews in Oncology/Hematology
The incidence of ALK inhibitor-related pneumonitis in advanced non-small-cell lung cancer patients: A systematic review and meta-analysis.2019Lung Cancer
Meta-analysis of overall incidence and risk of ALK inhibitors-induced liver toxicities in advanced non-small-cell lung cancer.2019Medicine
Crizotinib Versus Chemotherapy on ALK-positive NSCLC: A Systematic Review of Efficacy and Safety.2019Current Cancer Drug Targets
Anaplastic Lymphoma Kinase Inhibitors for Advanced Non-Small Cell Lung Carcinoma.2019CADTH
Incidence and risk of hepatic toxicities associated with anaplastic lymphoma kinase inhibitors in the treatment of non-small-cell lung cancer: a systematic review and meta-analysis.2018Oncotarget
Ceritinib alone for crizotinib-naive versus crizotinib-pretreated for management of anaplastic lymphoma kinase-rearrangement non–small-cell lung cancer: a systematic review.2018Clinical Lung Cancer
Systematic review and meta-analysis of selected toxicities of approved ALK inhibitors in metastatic non-small cell lung cancer.2018Oncotarget
The efficacy and safety of alectinib in the treatment of ALK+ NSCLC: a systematic review and meta-analysis.2018Onco Targets and Therapy
Lung Toxicity in Non-Small-Cell Lung Cancer Patients Exposed to ALK Inhibitors: Report of a Peculiar Case and Systematic Review of the Literature.2018Clinical Lung Cancer

Clinical Practice Guidelines